董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Keelung Hong | 男 | Chief Executive Officer, Founder and Chairman | 76 | 784.53万 | 未持股 | 2020-03-10 |
| Shieh Shung Tom Chen | 男 | Director | 68 | 20.00万 | 未持股 | 2020-03-10 |
| May Kang | 女 | Director | 49 | 19.00万 | 未持股 | 2020-03-10 |
| Chan Yu Lee | 男 | Director | 48 | 20.00万 | 未持股 | 2020-03-10 |
| Moun Rong Lin | 男 | Director | 64 | 20.00万 | 未持股 | 2020-03-10 |
| Beatrice Liu | 女 | Director | 55 | 20.00万 | 未持股 | 2020-03-10 |
| Horng Dar Lin | 男 | Director | 51 | 未披露 | 未持股 | 2020-03-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Keelung Hong | 男 | Chief Executive Officer, Founder and Chairman | 76 | 784.53万 | 未持股 | 2020-03-10 |
| George Yeh | 男 | President | 47 | 715.86万 | 未持股 | 2020-03-10 |
| Nicole Lin | 女 | Vice President in Finance and Administration | 54 | 461.22万 | 未持股 | 2020-03-10 |
| Yunlong Tseng | 男 | Vice President, Research & Development | 53 | 376.47万 | 未持股 | 2020-03-10 |
| Wenji Chen | -- | Vice President, Corporate Development | 60 | 401.05万 | 未持股 | 2020-03-10 |
| George Spencer Green | 男 | Chief Medical Officer | 73 | 966.66万 | 未持股 | 2020-03-10 |
| Vincent Chang | 男 | Vice President of Manufacturing Development | 65 | 55.23万 | 未持股 | 2020-03-10 |
董事简历
中英对照 | 中文 | 英文- Keelung Hong
-
Keelung Hong于1997年创立了TLC，并自2002年以来担任我们的董事会主席，自2005年以来担任首席执行官。在担任首席执行官之前，洪博士于1997年至2004年担任我们的科技顾问。洪博士联合创立了Hermes Biosciences，Inc.，并于1999年至2005年担任其首席科学官。在涉足药物开发领域之前，洪博士于1998年至2002年担任加利福尼亚太平洋医学中心研究所的研究科学家，在此之前，他是加利福尼亚大学癌症研究所脂质体研究实验室的科学家，1979年至1998年在旧金山。洪博士多年来还担任多家生物制药公司的顾问。洪博士在加州大学伯克利分校获得化学博士学位，在得克萨斯大学埃尔帕索分校获得化学硕士学位，在台湾成功大学获得化学学士学位。
Keelung Hong founded TLC in 1997 and has served as our Chairman of the board of directors since 2002 and Chief Executive Officer since 2005. Prior to serving as CEO, Dr. Hong served as our Science and Technology Adviser from 1997 to 2004. Dr. Hong co-founded Hermes Biosciences, Inc. and served as its Chief Scientific Officer from 1999 to 2005. Before venturing into the world of drug development, Dr. Hong was a Research Scientist for the California Pacific Medical Center Research Institute from 1998 to 2002 prior to which he was a Scientist at the Liposome Research Laboratory at the Cancer Research Institute of the University of California, San Francisco from 1979 to 1998. Dr. Hong has also served as consultant to various biopharmaceutical companies over the years. Dr. Hong received a Ph.D. in Chemistry from the University of California, Berkeley, an M.S. in Chemistry from the University of Texas at El Paso, and a B.S. in Chemistry from Taiwan Cheng Kung University. - Keelung Hong于1997年创立了TLC，并自2002年以来担任我们的董事会主席，自2005年以来担任首席执行官。在担任首席执行官之前，洪博士于1997年至2004年担任我们的科技顾问。洪博士联合创立了Hermes Biosciences，Inc.，并于1999年至2005年担任其首席科学官。在涉足药物开发领域之前，洪博士于1998年至2002年担任加利福尼亚太平洋医学中心研究所的研究科学家，在此之前，他是加利福尼亚大学癌症研究所脂质体研究实验室的科学家，1979年至1998年在旧金山。洪博士多年来还担任多家生物制药公司的顾问。洪博士在加州大学伯克利分校获得化学博士学位，在得克萨斯大学埃尔帕索分校获得化学硕士学位，在台湾成功大学获得化学学士学位。
- Keelung Hong founded TLC in 1997 and has served as our Chairman of the board of directors since 2002 and Chief Executive Officer since 2005. Prior to serving as CEO, Dr. Hong served as our Science and Technology Adviser from 1997 to 2004. Dr. Hong co-founded Hermes Biosciences, Inc. and served as its Chief Scientific Officer from 1999 to 2005. Before venturing into the world of drug development, Dr. Hong was a Research Scientist for the California Pacific Medical Center Research Institute from 1998 to 2002 prior to which he was a Scientist at the Liposome Research Laboratory at the Cancer Research Institute of the University of California, San Francisco from 1979 to 1998. Dr. Hong has also served as consultant to various biopharmaceutical companies over the years. Dr. Hong received a Ph.D. in Chemistry from the University of California, Berkeley, an M.S. in Chemistry from the University of Texas at El Paso, and a B.S. in Chemistry from Taiwan Cheng Kung University.
- Shieh Shung Tom Chen
-
Shieh Shung Tom Chen自2017年5月以来一直担任我们的董事会成员。他曾担任Optimer Biotechnology公司的Vice President（从2005年到2009年10月退休）。在此之前，Tom Chen博士从2002年到2005年担任台湾Biotechnology Development Center药物开发项目主管。在此之前，Tom Chen博士于1981年至2001年间担任默克研究实验室（Merck Research Laboratories）的高级微生物学家，研究员和药物发现和开发计划的高级调查人员。Tom Chen博士在普渡大学（Purdue University）获得药物化学博士学位，在台湾国立清华大学（National Tsing Hua University）获得化学学士学位。
Shieh Shung Tom Chen has served as a member of our board of directors since May 2017. He served as vice president at Optimer Biotechnology Inc. from 2005 until he retired in October 2009. Prior to that, Dr. Tom Chen served as the head of the drug development program at the Development Center for Biotechnology in Taiwan from 2002 to 2005. Before that, Dr. Tom Chen held the roles of Senior Microbiologist, Research Fellow, and Senior Investigation in drug discovery and development programs at Merck Research Laboratories between 1981 and 2001. Dr. Tom Chen received a Ph.D. in Medicinal Chemistry from Purdue University, and a B.S. in Chemistry from National Tsing Hua University, Taiwan. - Shieh Shung Tom Chen自2017年5月以来一直担任我们的董事会成员。他曾担任Optimer Biotechnology公司的Vice President（从2005年到2009年10月退休）。在此之前，Tom Chen博士从2002年到2005年担任台湾Biotechnology Development Center药物开发项目主管。在此之前，Tom Chen博士于1981年至2001年间担任默克研究实验室（Merck Research Laboratories）的高级微生物学家，研究员和药物发现和开发计划的高级调查人员。Tom Chen博士在普渡大学（Purdue University）获得药物化学博士学位，在台湾国立清华大学（National Tsing Hua University）获得化学学士学位。
- Shieh Shung Tom Chen has served as a member of our board of directors since May 2017. He served as vice president at Optimer Biotechnology Inc. from 2005 until he retired in October 2009. Prior to that, Dr. Tom Chen served as the head of the drug development program at the Development Center for Biotechnology in Taiwan from 2002 to 2005. Before that, Dr. Tom Chen held the roles of Senior Microbiologist, Research Fellow, and Senior Investigation in drug discovery and development programs at Merck Research Laboratories between 1981 and 2001. Dr. Tom Chen received a Ph.D. in Medicinal Chemistry from Purdue University, and a B.S. in Chemistry from National Tsing Hua University, Taiwan.
- May Kang
-
May Kang自2012年以来一直担任我们的董事会成员。Kang女士目前是Fun-I Investment Co.的董事长，自2012年起担任该职位。Kang女士担任LaFresh Information Technology Co.的首席执行官，并担任LaFresh Information Technology and IF Technology Company Co.的董事。Kang女士于2013年11月至2016年12月担任IF Technology Company Co.首席执行官。在此之前，康女士于2006年至2011年在Waterland Securities Co.Ltd（一家经纪公司）担任总经理。在此之前，康女士于2002年至2006年担任元大SITC元大基金（一家资产管理公司）的Vice President，并于1993年至2006年担任元大证券有限公司（一家金融服务公司）的首席投资官。姜女士在国立台湾大学获得工商管理硕士学位，并获得工商管理学士学位。国立台湾大学国际贸易学士学位。
May Kang has served as a member of our board of directors since 2012. Ms. Kang is currently the Chairman at Fun-I Investment Co., where she has held the position since 2012. Ms. Kang serves as Chief Executive Officer of Lafresh Information Technology Co., and as director of Lafresh Information Technology and IF Technology Company Co. Ms. Kang served as Chief Executive Officer of IF Technology Company Co. from November 2013 to December 2016. Prior to that, Ms. Kang served as the general manager at Waterland Securities Co. Ltd, a brokerage company, from 2006 to 2011. Before that, Ms. Kang served as Vice President at Yuanta SITC Yuanta Funds, an asset management company, from 2002 to 2006 and as Chief Investment Officer with Yuanta Securities Co. Ltd., a finance service company, from 1993 to 2006. Ms. Kang received an M.B.A. from National Taiwan University, and a B.Com. in International Trade from National Taiwan University. - May Kang自2012年以来一直担任我们的董事会成员。Kang女士目前是Fun-I Investment Co.的董事长，自2012年起担任该职位。Kang女士担任LaFresh Information Technology Co.的首席执行官，并担任LaFresh Information Technology and IF Technology Company Co.的董事。Kang女士于2013年11月至2016年12月担任IF Technology Company Co.首席执行官。在此之前，康女士于2006年至2011年在Waterland Securities Co.Ltd（一家经纪公司）担任总经理。在此之前，康女士于2002年至2006年担任元大SITC元大基金（一家资产管理公司）的Vice President，并于1993年至2006年担任元大证券有限公司（一家金融服务公司）的首席投资官。姜女士在国立台湾大学获得工商管理硕士学位，并获得工商管理学士学位。国立台湾大学国际贸易学士学位。
- May Kang has served as a member of our board of directors since 2012. Ms. Kang is currently the Chairman at Fun-I Investment Co., where she has held the position since 2012. Ms. Kang serves as Chief Executive Officer of Lafresh Information Technology Co., and as director of Lafresh Information Technology and IF Technology Company Co. Ms. Kang served as Chief Executive Officer of IF Technology Company Co. from November 2013 to December 2016. Prior to that, Ms. Kang served as the general manager at Waterland Securities Co. Ltd, a brokerage company, from 2006 to 2011. Before that, Ms. Kang served as Vice President at Yuanta SITC Yuanta Funds, an asset management company, from 2002 to 2006 and as Chief Investment Officer with Yuanta Securities Co. Ltd., a finance service company, from 1993 to 2006. Ms. Kang received an M.B.A. from National Taiwan University, and a B.Com. in International Trade from National Taiwan University.
- Chan Yu Lee
-
Chan Yu Lee投资有限公司自2014年6月以来一直担任我们的董事会成员。Lee先生自2014年6月起担任Chang Xiang Investment Company，Ltd.的董事会代表。在此之前，Lee先生于2012年4月至2014年5月从事金融投资。Lee先生在爱荷华大学（University of Iowa）获得精算硕士学位。Lee先生拥有西雅图大学（Seattle University）金融学硕士学位和台湾淡江大学（Tamkang University）工商管理硕士学位。
Chan Yu Lee Investment Company, Ltd. has served as a member of our board of directors since June 2014. Mr. Lee has served as Chang Xiang Investment Company, Ltd.’s representative to our board of directors since June 2014. Prior to that, Mr. Lee was self employed in financial investments from April 2012 to May 2014. Mr. Lee received an M.S. in Actuarial Science from the University of Iowa. Mr. Lee has an M.S. in Finance from Seattle University and a B.A. from Tamkang University in Taiwan. - Chan Yu Lee投资有限公司自2014年6月以来一直担任我们的董事会成员。Lee先生自2014年6月起担任Chang Xiang Investment Company，Ltd.的董事会代表。在此之前，Lee先生于2012年4月至2014年5月从事金融投资。Lee先生在爱荷华大学（University of Iowa）获得精算硕士学位。Lee先生拥有西雅图大学（Seattle University）金融学硕士学位和台湾淡江大学（Tamkang University）工商管理硕士学位。
- Chan Yu Lee Investment Company, Ltd. has served as a member of our board of directors since June 2014. Mr. Lee has served as Chang Xiang Investment Company, Ltd.’s representative to our board of directors since June 2014. Prior to that, Mr. Lee was self employed in financial investments from April 2012 to May 2014. Mr. Lee received an M.S. in Actuarial Science from the University of Iowa. Mr. Lee has an M.S. in Finance from Seattle University and a B.A. from Tamkang University in Taiwan.
- Moun Rong Lin
-
Moun Rong Lin自2017年5月以来一直担任我们的董事会成员。他是Nan Hsin Investment Limited Company（投资公司）的主席，在那里他曾一直担任职务（2001年以来）。在此之前，林先生于1995年至1999年担任H&Q Taiwan Co.，Ltd.（一家投资公司）的总裁，同时担任H&Q Asia Pacific（一家私募股权公司和H&Q Taiwan Co.，Ltd.的母公司）的董事总经理。从1987年到1995年，林先生在H&；Q Taiwan Co.，Ltd.担任多个投资职位，从经理到Vice President。林先生在国立交通大学获得工商管理硕士学位，在国立台湾大学获得工商管理硕士学位。
Moun Rong Lin has served as a member of our board of directors since May 2017. Mr. Lin is the Chairman at Nan Hsin Investment Limited Company, an investment firm, where he has held the position since 2001. Prior to that, Mr. Lin served as President of H&Q Taiwan Co., Ltd., an investment firm, from 1995 to 1999 whilst concurrently serving as a managing director of H&Q Asia Pacific, a private equity firm and the parent company of H&Q Taiwan Co., Ltd. From 1987 to 1995 Mr. Lin served in various investment positions from manager to vice president at H&Q Taiwan Co., Ltd. Mr. Lin received an M.B.A from National Chiao Tung University and a B.S. degree from National Taiwan University. - Moun Rong Lin自2017年5月以来一直担任我们的董事会成员。他是Nan Hsin Investment Limited Company（投资公司）的主席，在那里他曾一直担任职务（2001年以来）。在此之前，林先生于1995年至1999年担任H&Q Taiwan Co.，Ltd.（一家投资公司）的总裁，同时担任H&Q Asia Pacific（一家私募股权公司和H&Q Taiwan Co.，Ltd.的母公司）的董事总经理。从1987年到1995年，林先生在H&；Q Taiwan Co.，Ltd.担任多个投资职位，从经理到Vice President。林先生在国立交通大学获得工商管理硕士学位，在国立台湾大学获得工商管理硕士学位。
- Moun Rong Lin has served as a member of our board of directors since May 2017. Mr. Lin is the Chairman at Nan Hsin Investment Limited Company, an investment firm, where he has held the position since 2001. Prior to that, Mr. Lin served as President of H&Q Taiwan Co., Ltd., an investment firm, from 1995 to 1999 whilst concurrently serving as a managing director of H&Q Asia Pacific, a private equity firm and the parent company of H&Q Taiwan Co., Ltd. From 1987 to 1995 Mr. Lin served in various investment positions from manager to vice president at H&Q Taiwan Co., Ltd. Mr. Lin received an M.B.A from National Chiao Tung University and a B.S. degree from National Taiwan University.
- Beatrice Liu
-
Beatrice Liu自2011年6月以来一直担任我们的董事会成员。Liu博士目前是BDO Taiwan（一家会计师事务所）的合伙人，自1991年8月起担任该职位。刘博士也是Genovate Biotechnology Co.，Ltd.的董事，自2017年6月起担任该职位。刘博士还担任中华民国注册会计师协会全国联合会的理事，并是美国注册会计师协会的成员。刘博士在厦门大学获得会计学博士学位，在伊利诺伊大学香槟分校获得会计学硕士学位，在国立政治大学获得税务学学士学位。
Beatrice Liu has served as a member of Taiwan Liposome Company, Ltd. board of directors since June 2011. Dr. Liu is currently a partner at BDO Taiwan, an accounting firm, where she has held the position since August 1991. Dr. Liu is also the director at Genovate Biotechnology Co., Ltd., where she has held the position since June 2017. Dr. Liu also serves as the director of the National Federation of Certified Public Accountants Association, Taiwan, China and is a member of the American Institute of Certified Public Accounts. Dr. Liu received a Ph.D. in Accounting from Xiamen University, an M.A. in Accounting from the University of Illinois at Urbana-Champaign, and a B.S. in Taxation from National Cheng-Chi University. - Beatrice Liu自2011年6月以来一直担任我们的董事会成员。Liu博士目前是BDO Taiwan（一家会计师事务所）的合伙人，自1991年8月起担任该职位。刘博士也是Genovate Biotechnology Co.，Ltd.的董事，自2017年6月起担任该职位。刘博士还担任中华民国注册会计师协会全国联合会的理事，并是美国注册会计师协会的成员。刘博士在厦门大学获得会计学博士学位，在伊利诺伊大学香槟分校获得会计学硕士学位，在国立政治大学获得税务学学士学位。
- Beatrice Liu has served as a member of Taiwan Liposome Company, Ltd. board of directors since June 2011. Dr. Liu is currently a partner at BDO Taiwan, an accounting firm, where she has held the position since August 1991. Dr. Liu is also the director at Genovate Biotechnology Co., Ltd., where she has held the position since June 2017. Dr. Liu also serves as the director of the National Federation of Certified Public Accountants Association, Taiwan, China and is a member of the American Institute of Certified Public Accounts. Dr. Liu received a Ph.D. in Accounting from Xiamen University, an M.A. in Accounting from the University of Illinois at Urbana-Champaign, and a B.S. in Taxation from National Cheng-Chi University.
- Horng Dar Lin
-
Horng Dar Lin自2020年以来一直担任我们的董事会成员。林先生拥有超过10年的行业经验和领导能力。林先生自2018年12月起担任Tanvex Biopharma，Inc.的董事长，自2019年1月起担任AP Biosciences，Inc.的董事长，自2019年8月起担任Cho Pharma，Inc.的总裁。此前，林先生于2014年3月至2017年3月担任国际律师事务所Winston&Strawn LLP的合伙人。从2013年到2014年，他曾担任Sovereign Law Office（他创立的律师事务所）的唯一执业律师。从2010年到2013年，林先生担任鸿海精密IND的Vice President兼董事长特别助理。股份有限公司又名富士康集团，一家代工企业。从2006年到2009年，他曾担任Finnegan，Henderson，Farabow，Garrett&Dunner公司的国际律师事务所的高级律师。从2000年到2005年，林先生是台湾台北地方法院的法官。林先生获得了法学硕士学位。毕业于台湾台北哥伦比亚法学院和东吴大学，并获得台湾台北国立台湾大学化学学士学位。
Horng Dar Lin has served as a member of our board of directors since 2020. Mr. Lin has more than 10 years of industry experience and leadership. Mr. Lin has been the Chairman of Tanvex BioPharma, Inc. since December 2018 Chairman of AP Biosciences, Inc. since January 2019 and President of Cho Pharma, Inc. since August 2019. Previously, Mr. Lin was a Partner of Winston & Strawn LLP, an international law firm, from March 2014 to March 2017. From 2013 to 2014 Mr. Lin was a sole practitioner at Sovereign Law Office, a law firm which he founded. From 2010 to 2013 Mr. Lin was a Vice President and special assistant to Chairman at Hon Hai Precision Ind. Co., Ltd. aka Foxconn Group, a contract manufacturing company. From 2006 to 2009 he was a senior attorney at the international law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. From 2000 to 2005 Mr. Lin was a Judge at Taiwan Taipei District Court. Mr. Lin earned his LL.M. from Columbia Law School and Soochow University in Taipei, Taiwan, and Bachelor’s degree in Chemistry from National Taiwan University in Taipei, Taiwan. - Horng Dar Lin自2020年以来一直担任我们的董事会成员。林先生拥有超过10年的行业经验和领导能力。林先生自2018年12月起担任Tanvex Biopharma，Inc.的董事长，自2019年1月起担任AP Biosciences，Inc.的董事长，自2019年8月起担任Cho Pharma，Inc.的总裁。此前，林先生于2014年3月至2017年3月担任国际律师事务所Winston&Strawn LLP的合伙人。从2013年到2014年，他曾担任Sovereign Law Office（他创立的律师事务所）的唯一执业律师。从2010年到2013年，林先生担任鸿海精密IND的Vice President兼董事长特别助理。股份有限公司又名富士康集团，一家代工企业。从2006年到2009年，他曾担任Finnegan，Henderson，Farabow，Garrett&Dunner公司的国际律师事务所的高级律师。从2000年到2005年，林先生是台湾台北地方法院的法官。林先生获得了法学硕士学位。毕业于台湾台北哥伦比亚法学院和东吴大学，并获得台湾台北国立台湾大学化学学士学位。
- Horng Dar Lin has served as a member of our board of directors since 2020. Mr. Lin has more than 10 years of industry experience and leadership. Mr. Lin has been the Chairman of Tanvex BioPharma, Inc. since December 2018 Chairman of AP Biosciences, Inc. since January 2019 and President of Cho Pharma, Inc. since August 2019. Previously, Mr. Lin was a Partner of Winston & Strawn LLP, an international law firm, from March 2014 to March 2017. From 2013 to 2014 Mr. Lin was a sole practitioner at Sovereign Law Office, a law firm which he founded. From 2010 to 2013 Mr. Lin was a Vice President and special assistant to Chairman at Hon Hai Precision Ind. Co., Ltd. aka Foxconn Group, a contract manufacturing company. From 2006 to 2009 he was a senior attorney at the international law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. From 2000 to 2005 Mr. Lin was a Judge at Taiwan Taipei District Court. Mr. Lin earned his LL.M. from Columbia Law School and Soochow University in Taipei, Taiwan, and Bachelor’s degree in Chemistry from National Taiwan University in Taipei, Taiwan.
高管简历
中英对照 | 中文 | 英文- Keelung Hong
Keelung Hong于1997年创立了TLC，并自2002年以来担任我们的董事会主席，自2005年以来担任首席执行官。在担任首席执行官之前，洪博士于1997年至2004年担任我们的科技顾问。洪博士联合创立了Hermes Biosciences，Inc.，并于1999年至2005年担任其首席科学官。在涉足药物开发领域之前，洪博士于1998年至2002年担任加利福尼亚太平洋医学中心研究所的研究科学家，在此之前，他是加利福尼亚大学癌症研究所脂质体研究实验室的科学家，1979年至1998年在旧金山。洪博士多年来还担任多家生物制药公司的顾问。洪博士在加州大学伯克利分校获得化学博士学位，在得克萨斯大学埃尔帕索分校获得化学硕士学位，在台湾成功大学获得化学学士学位。
Keelung Hong founded TLC in 1997 and has served as our Chairman of the board of directors since 2002 and Chief Executive Officer since 2005. Prior to serving as CEO, Dr. Hong served as our Science and Technology Adviser from 1997 to 2004. Dr. Hong co-founded Hermes Biosciences, Inc. and served as its Chief Scientific Officer from 1999 to 2005. Before venturing into the world of drug development, Dr. Hong was a Research Scientist for the California Pacific Medical Center Research Institute from 1998 to 2002 prior to which he was a Scientist at the Liposome Research Laboratory at the Cancer Research Institute of the University of California, San Francisco from 1979 to 1998. Dr. Hong has also served as consultant to various biopharmaceutical companies over the years. Dr. Hong received a Ph.D. in Chemistry from the University of California, Berkeley, an M.S. in Chemistry from the University of Texas at El Paso, and a B.S. in Chemistry from Taiwan Cheng Kung University.- Keelung Hong于1997年创立了TLC，并自2002年以来担任我们的董事会主席，自2005年以来担任首席执行官。在担任首席执行官之前，洪博士于1997年至2004年担任我们的科技顾问。洪博士联合创立了Hermes Biosciences，Inc.，并于1999年至2005年担任其首席科学官。在涉足药物开发领域之前，洪博士于1998年至2002年担任加利福尼亚太平洋医学中心研究所的研究科学家，在此之前，他是加利福尼亚大学癌症研究所脂质体研究实验室的科学家，1979年至1998年在旧金山。洪博士多年来还担任多家生物制药公司的顾问。洪博士在加州大学伯克利分校获得化学博士学位，在得克萨斯大学埃尔帕索分校获得化学硕士学位，在台湾成功大学获得化学学士学位。
- Keelung Hong founded TLC in 1997 and has served as our Chairman of the board of directors since 2002 and Chief Executive Officer since 2005. Prior to serving as CEO, Dr. Hong served as our Science and Technology Adviser from 1997 to 2004. Dr. Hong co-founded Hermes Biosciences, Inc. and served as its Chief Scientific Officer from 1999 to 2005. Before venturing into the world of drug development, Dr. Hong was a Research Scientist for the California Pacific Medical Center Research Institute from 1998 to 2002 prior to which he was a Scientist at the Liposome Research Laboratory at the Cancer Research Institute of the University of California, San Francisco from 1979 to 1998. Dr. Hong has also served as consultant to various biopharmaceutical companies over the years. Dr. Hong received a Ph.D. in Chemistry from the University of California, Berkeley, an M.S. in Chemistry from the University of Texas at El Paso, and a B.S. in Chemistry from Taiwan Cheng Kung University.
- George Yeh
George Yeh自2002年以来一直担任TLC的总裁。在加入TLC之前，Yeh先生从1999年到2002年担任AsiaWired Group，Inc.（一家风险咨询公司）的Vice President。在AsiaWired Group之前，Yeh先生是General Bank（一家位于美国的商业银行）的合伙人。从2002年到2005年，叶先生还担任爱马仕生物科学公司（Hermes Biosciences，Inc.）的首席财务官，在那里他首次开始与Keelung Hong博士共事。叶先生在密歇根大学（University of Michigan）获得建筑硕士学位和工商管理硕士学位。他在University of California，Berkeley获得建筑学学士学位。
George Yeh has served as the President of TLC since 2002. Prior to joining TLC, Mr. Yeh was Vice President of AsiaWired Group, Inc., a venture advisory company, from 1999 to 2002. Before AsiaWired Group, Mr. Yeh was an associate at General Bank, a U.S.-based commercial bank. Mr. Yeh also served as the Chief Financial Officer of Hermes Biosciences, Inc. from 2002 to 2005 where he first started working alongside Dr. Keelung Hong. Mr. Yeh received a Master of Architecture and an M.B.A. from the University of Michigan. He received a B.A. in Architecture from the University of California, Berkeley.- George Yeh自2002年以来一直担任TLC的总裁。在加入TLC之前，Yeh先生从1999年到2002年担任AsiaWired Group，Inc.（一家风险咨询公司）的Vice President。在AsiaWired Group之前，Yeh先生是General Bank（一家位于美国的商业银行）的合伙人。从2002年到2005年，叶先生还担任爱马仕生物科学公司（Hermes Biosciences，Inc.）的首席财务官，在那里他首次开始与Keelung Hong博士共事。叶先生在密歇根大学（University of Michigan）获得建筑硕士学位和工商管理硕士学位。他在University of California，Berkeley获得建筑学学士学位。
- George Yeh has served as the President of TLC since 2002. Prior to joining TLC, Mr. Yeh was Vice President of AsiaWired Group, Inc., a venture advisory company, from 1999 to 2002. Before AsiaWired Group, Mr. Yeh was an associate at General Bank, a U.S.-based commercial bank. Mr. Yeh also served as the Chief Financial Officer of Hermes Biosciences, Inc. from 2002 to 2005 where he first started working alongside Dr. Keelung Hong. Mr. Yeh received a Master of Architecture and an M.B.A. from the University of Michigan. He received a B.A. in Architecture from the University of California, Berkeley.
- Nicole Lin
Nicole Lin自2014年以来一直担任我们的财务和行政Vice President。在此之前，林女士于2005年至2013年担任我们的董事兼财务总监。在加入我们之前，Lin女士于2004年在Malab Inc.（一家计算机组件分销商）担任会计主管。在此之前，Lin从2001年到2004年担任NextGen Communications（一家高科技初创公司）会计经理。Lin从1998年到2001年担任General Bank（一家美国商业银行）高科技/风险部门商业信贷官，获得金融和银行经验。林女士于1995年至1998年担任台湾证券股份有限公司（一家证券公司）的证券承销商，并于1990年至1995年担任Rick Chen会计师事务所的证券承销商。林女士在加州大学河滨分校获得工商管理硕士学位，并在台湾台北东吴大学获得国际贸易学士学位。她是美国注册会计师。
Nicole Lin has served as our Vice President in Finance and Administration since 2014. Prior to that, Ms. Lin served as our Director and controller from 2005 to 2013. Before joining us, Ms. Lin served as Accounting Supervisor at MaLab Inc., a computer component distributor, in 2004. Before that, Ms. Lin served as Accounting Manager at NextGen Communications, a high-technology start up, from 2001 to 2004. Ms. Lin obtained finance and banking experience when she served as Commercial Loan Officer within the High Tech/Venture Division of General Bank, a U.S.-based commercial bank, from 1998 to 2001. Ms. Lin served as Security Underwriter at Taiwan Securities Co., Ltd., a securities firm, from 1995 to 1998 and at Rick Chen CPA Firm from 1990 to 1995. Ms. Lin received her M.B.A from the University of California, Riverside and her Bachelors in International Trade from Soochow University in Taipei, Taiwan. She is a U.S. Certified Public Accountant.- Nicole Lin自2014年以来一直担任我们的财务和行政Vice President。在此之前，林女士于2005年至2013年担任我们的董事兼财务总监。在加入我们之前，Lin女士于2004年在Malab Inc.（一家计算机组件分销商）担任会计主管。在此之前，Lin从2001年到2004年担任NextGen Communications（一家高科技初创公司）会计经理。Lin从1998年到2001年担任General Bank（一家美国商业银行）高科技/风险部门商业信贷官，获得金融和银行经验。林女士于1995年至1998年担任台湾证券股份有限公司（一家证券公司）的证券承销商，并于1990年至1995年担任Rick Chen会计师事务所的证券承销商。林女士在加州大学河滨分校获得工商管理硕士学位，并在台湾台北东吴大学获得国际贸易学士学位。她是美国注册会计师。
- Nicole Lin has served as our Vice President in Finance and Administration since 2014. Prior to that, Ms. Lin served as our Director and controller from 2005 to 2013. Before joining us, Ms. Lin served as Accounting Supervisor at MaLab Inc., a computer component distributor, in 2004. Before that, Ms. Lin served as Accounting Manager at NextGen Communications, a high-technology start up, from 2001 to 2004. Ms. Lin obtained finance and banking experience when she served as Commercial Loan Officer within the High Tech/Venture Division of General Bank, a U.S.-based commercial bank, from 1998 to 2001. Ms. Lin served as Security Underwriter at Taiwan Securities Co., Ltd., a securities firm, from 1995 to 1998 and at Rick Chen CPA Firm from 1990 to 1995. Ms. Lin received her M.B.A from the University of California, Riverside and her Bachelors in International Trade from Soochow University in Taipei, Taiwan. She is a U.S. Certified Public Accountant.
- Yunlong Tseng
Yunlong Tseng自2014年1月起担任研究与开发Vice President。在担任该职位之前，曾博士于2002年至2013年12月担任我们的研究与开发总监。在加入TLC之前，曾博士在国立台湾大学医院肿瘤科进行博士后研究。Tseng博士在台湾国立台湾大学医学院（National Taiwan University，College of Medicine）获得生物化学博士学位，在台湾淡江大学（Tamkang University）获得化学学士学位。
Yunlong Tseng has served as our Vice President of Research and Development since January 2014. Prior to holding that position, Dr. Tseng was our Director of Research and Development from 2002 to December 2013. Prior to joining TLC, Dr. Tseng conducted his postdoctoral research at the Department of Oncology at National Taiwan University Hospital. Dr. Tseng received a Ph.D. in Biochemistry from National Taiwan University, College of Medicine, and a B.S. in Chemistry from Tamkang University, Taiwan.- Yunlong Tseng自2014年1月起担任研究与开发Vice President。在担任该职位之前，曾博士于2002年至2013年12月担任我们的研究与开发总监。在加入TLC之前，曾博士在国立台湾大学医院肿瘤科进行博士后研究。Tseng博士在台湾国立台湾大学医学院（National Taiwan University，College of Medicine）获得生物化学博士学位，在台湾淡江大学（Tamkang University）获得化学学士学位。
- Yunlong Tseng has served as our Vice President of Research and Development since January 2014. Prior to holding that position, Dr. Tseng was our Director of Research and Development from 2002 to December 2013. Prior to joining TLC, Dr. Tseng conducted his postdoctoral research at the Department of Oncology at National Taiwan University Hospital. Dr. Tseng received a Ph.D. in Biochemistry from National Taiwan University, College of Medicine, and a B.S. in Chemistry from Tamkang University, Taiwan.
- Wenji Chen
Wenji Chen自2016年10月起担任公司发展Vice President。在加入TLC之前，陈博士于2016年1月至2016年8月担任台湾生物技术发展中心产业促进Vice President。在此之前，陈博士于2010年至2015年12月担任中国上海葛兰素史克中国研发有限公司全球业务发展高级总监。Chen从2006年到2010年担任GlaxoSmithKline LLC（位于北卡罗来纳州研究三角公园设施）全球业务开发主管，从2002年到2005年担任Norak Biosciences Inc.（一家生物技术公司）业务开发主管。从1992年到2002年，陈博士是葛兰素史克公司在北卡罗来纳州三角研究园区的研究与开发部门的首席研究员。陈博士在德克萨斯大学西南医学中心获得博士学位，在北卡罗来纳大学教堂山分校获得工商管理硕士学位，在台湾台北国立台湾大学获得工商管理硕士学位。
Wenji Chen has served as our Vice President of Corporate Development since October 2016. Before joining TLC, Dr. Chen was the Vice President of Industrial Promotion at the Development Center of Biotechnology in Taiwan from January 2016 to August 2016. Prior to that, Dr. Chen was Senior Director of Worldwide Business Development at GlaxoSmithKline China R&D Co., Ltd. in Shanghai, China from 2010 to December 2015. Dr. Chen served as Director of Worldwide Business Development at GlaxoSmithKline LLC in the Research Triangle Park facility in North Carolina from 2006 to 2010 and Business Development Director at Norak Biosciences Inc., a biotechnology firm, from 2002 to 2005. From 1992 to 2002 Dr. Chen was a principle investigator in the Research and Development Division of GlaxoSmithKline in the Research Triangle Park facility in North Carolina. Dr. Chen received a Ph.D. from the University of Texas Southwestern Medical Center, an M.B.A. from the University of North Carolina, Chapel Hill, and a B.S. from National Taiwan University, Taipei, Taiwan.- Wenji Chen自2016年10月起担任公司发展Vice President。在加入TLC之前，陈博士于2016年1月至2016年8月担任台湾生物技术发展中心产业促进Vice President。在此之前，陈博士于2010年至2015年12月担任中国上海葛兰素史克中国研发有限公司全球业务发展高级总监。Chen从2006年到2010年担任GlaxoSmithKline LLC（位于北卡罗来纳州研究三角公园设施）全球业务开发主管，从2002年到2005年担任Norak Biosciences Inc.（一家生物技术公司）业务开发主管。从1992年到2002年，陈博士是葛兰素史克公司在北卡罗来纳州三角研究园区的研究与开发部门的首席研究员。陈博士在德克萨斯大学西南医学中心获得博士学位，在北卡罗来纳大学教堂山分校获得工商管理硕士学位，在台湾台北国立台湾大学获得工商管理硕士学位。
- Wenji Chen has served as our Vice President of Corporate Development since October 2016. Before joining TLC, Dr. Chen was the Vice President of Industrial Promotion at the Development Center of Biotechnology in Taiwan from January 2016 to August 2016. Prior to that, Dr. Chen was Senior Director of Worldwide Business Development at GlaxoSmithKline China R&D Co., Ltd. in Shanghai, China from 2010 to December 2015. Dr. Chen served as Director of Worldwide Business Development at GlaxoSmithKline LLC in the Research Triangle Park facility in North Carolina from 2006 to 2010 and Business Development Director at Norak Biosciences Inc., a biotechnology firm, from 2002 to 2005. From 1992 to 2002 Dr. Chen was a principle investigator in the Research and Development Division of GlaxoSmithKline in the Research Triangle Park facility in North Carolina. Dr. Chen received a Ph.D. from the University of Texas Southwestern Medical Center, an M.B.A. from the University of North Carolina, Chapel Hill, and a B.S. from National Taiwan University, Taipei, Taiwan.
- George Spencer Green
George Spencer Green自2019年1月起担任首席医疗官。在加入TLC之前，Spencer-Green博士曾于2012年至2015年担任辉瑞生物仿制药开发计划的前任Vice President兼临床负责人，他领导的团队设计并启动了五项资产的临床开发计划（从1期到3期）。任职Pfizer公司之前，他曾担任Vertex Pharmaceuticals公司的高级医疗董事（从2007年到2011年），在那里他曾领导类风湿性关节炎和囊性纤维化的临床开发计划的设计和执行。在加入Vertex之前，Spencer-Green博士从2002年到2005年担任雅培公司全球医疗总监，是Humira类风湿性关节炎注册和长期扩展项目的临床负责人。在雅培公司之前，Spencer-Green博士从1998年到2002年担任Immunex Corporation Enbrel的特许医疗总监，Enbrel是第一个被批准用于治疗类风湿性关节炎的靶向生物疗法。Spencer-Green博士在华盛顿大学医学院（University of Washington Medical School）、达特茅斯医学院（Dartmouth Medical School）和辛辛那提大学医学中心（University of Cincinnati Medical Center）担任医学副教授。Spencer-Green博士在俄亥俄州欧柏林的欧柏林学院（Oberlin College）获得学士学位，在纽约哥伦比亚大学内科医生和外科医生学院（Columbia University College of Physicians and Surgeons）获得医学博士学位，在新罕布什尔州汉诺威的达特茅斯学院（Dartmouth College）获得临床评估科学硕士学位。
George Spencer Green has served as our Chief Medical Officer since January 2019. Prior to joining TLC, Dr. Spencer-Green served as the prior Vice President and clinical head of Pfizer’s biosimilars development program from 2012 to 2015 where he led the team that designed and initiated clinical development plans from Phase 1 to Phase 3 for five assets. Prior to Pfizer, Dr. Spencer-Green served as the Senior Medical Director at Vertex Pharmaceuticals, Inc. from 2007 to 2011 where he led the design and execution of clinical development programs in rheumatoid arthritis and cystic fibrosis. Prior to Vertex, Dr. Spencer-Green was the Global Medical Director at Abbott Laboratories from 2002 to 2005 and was the clinical lead for the rheumatoid arthritis registration and long-term extension programs for Humira. Prior to Abbott Laboratories, Dr. Spencer-Green was Franchise Medical Director at Immunex Corporation from 1998 to 2002 for Enbrel, the first targeted biologic treatment approved for the treatment of rheumatoid arthritis. Dr. Spencer-Green served as Associate Professor of Medicine at University of Washington Medical School, Dartmouth Medical School and University of Cincinnati Medical Center. Dr. Spencer-Green received his B.A. from Oberlin College in Oberlin, Ohio, his M.D. from Columbia University College of Physicians and Surgeons in New York, New York, and his M.S. in Clinical Evaluative Science from Dartmouth College in Hanover, New Hampshire.- George Spencer Green自2019年1月起担任首席医疗官。在加入TLC之前，Spencer-Green博士曾于2012年至2015年担任辉瑞生物仿制药开发计划的前任Vice President兼临床负责人，他领导的团队设计并启动了五项资产的临床开发计划（从1期到3期）。任职Pfizer公司之前，他曾担任Vertex Pharmaceuticals公司的高级医疗董事（从2007年到2011年），在那里他曾领导类风湿性关节炎和囊性纤维化的临床开发计划的设计和执行。在加入Vertex之前，Spencer-Green博士从2002年到2005年担任雅培公司全球医疗总监，是Humira类风湿性关节炎注册和长期扩展项目的临床负责人。在雅培公司之前，Spencer-Green博士从1998年到2002年担任Immunex Corporation Enbrel的特许医疗总监，Enbrel是第一个被批准用于治疗类风湿性关节炎的靶向生物疗法。Spencer-Green博士在华盛顿大学医学院（University of Washington Medical School）、达特茅斯医学院（Dartmouth Medical School）和辛辛那提大学医学中心（University of Cincinnati Medical Center）担任医学副教授。Spencer-Green博士在俄亥俄州欧柏林的欧柏林学院（Oberlin College）获得学士学位，在纽约哥伦比亚大学内科医生和外科医生学院（Columbia University College of Physicians and Surgeons）获得医学博士学位，在新罕布什尔州汉诺威的达特茅斯学院（Dartmouth College）获得临床评估科学硕士学位。
- George Spencer Green has served as our Chief Medical Officer since January 2019. Prior to joining TLC, Dr. Spencer-Green served as the prior Vice President and clinical head of Pfizer’s biosimilars development program from 2012 to 2015 where he led the team that designed and initiated clinical development plans from Phase 1 to Phase 3 for five assets. Prior to Pfizer, Dr. Spencer-Green served as the Senior Medical Director at Vertex Pharmaceuticals, Inc. from 2007 to 2011 where he led the design and execution of clinical development programs in rheumatoid arthritis and cystic fibrosis. Prior to Vertex, Dr. Spencer-Green was the Global Medical Director at Abbott Laboratories from 2002 to 2005 and was the clinical lead for the rheumatoid arthritis registration and long-term extension programs for Humira. Prior to Abbott Laboratories, Dr. Spencer-Green was Franchise Medical Director at Immunex Corporation from 1998 to 2002 for Enbrel, the first targeted biologic treatment approved for the treatment of rheumatoid arthritis. Dr. Spencer-Green served as Associate Professor of Medicine at University of Washington Medical School, Dartmouth Medical School and University of Cincinnati Medical Center. Dr. Spencer-Green received his B.A. from Oberlin College in Oberlin, Ohio, his M.D. from Columbia University College of Physicians and Surgeons in New York, New York, and his M.S. in Clinical Evaluative Science from Dartmouth College in Hanover, New Hampshire.
- Vincent Chang
Vincent Chang自2018年7月起担任我们的制造业发展Vice President。Chang博士还继续管理咨询公司Yili Consulting，LLC，该公司执行质量审计，并与客户合作进行质量改进和各种化学，制造和控制问题，他自2015年8月起管理该公司。在管理这家咨询公司之前，张博士在雅培公司工作了25年。在雅培公司的最后一个职位上，Chang博士担任第三方制造QA总监，负责从活性药物成分到多种剂型药物产品的合同制造的质量保证。Chang博士在密苏里大学圣路易斯分校（University of Missouri-St.Louis）获得无机化学硕士学位，并在杜克大学（Duke University）获得有机化学博士学位。
Vincent Chang has served as our Vice President of Manufacturing Development since July 2018. Dr. Chang also continues to manage a consulting firm, YiLi Consulting, LLC, that performs quality audits and works with clients on quality improvement and various chemistry, manufacturing and control issues, which he has managed since August 2015. Prior to his work managing the consulting firm, Dr. Chang was employed by Abbott Laboratories for 25 years. In his last role at Abbott Laboratories, Dr. Chang served as the Third Party Manufacturing QA Director, and was responsible for the quality assurance of contract manufacturing from active pharmaceutical ingredients to a wide range of dosage forms of drug products. Dr. Chang received his M.S. in inorganic chemistry from the University of Missouri - St. Louis and his Ph.D. in organic chemistry from Duke University.- Vincent Chang自2018年7月起担任我们的制造业发展Vice President。Chang博士还继续管理咨询公司Yili Consulting，LLC，该公司执行质量审计，并与客户合作进行质量改进和各种化学，制造和控制问题，他自2015年8月起管理该公司。在管理这家咨询公司之前，张博士在雅培公司工作了25年。在雅培公司的最后一个职位上，Chang博士担任第三方制造QA总监，负责从活性药物成分到多种剂型药物产品的合同制造的质量保证。Chang博士在密苏里大学圣路易斯分校（University of Missouri-St.Louis）获得无机化学硕士学位，并在杜克大学（Duke University）获得有机化学博士学位。
- Vincent Chang has served as our Vice President of Manufacturing Development since July 2018. Dr. Chang also continues to manage a consulting firm, YiLi Consulting, LLC, that performs quality audits and works with clients on quality improvement and various chemistry, manufacturing and control issues, which he has managed since August 2015. Prior to his work managing the consulting firm, Dr. Chang was employed by Abbott Laboratories for 25 years. In his last role at Abbott Laboratories, Dr. Chang served as the Third Party Manufacturing QA Director, and was responsible for the quality assurance of contract manufacturing from active pharmaceutical ingredients to a wide range of dosage forms of drug products. Dr. Chang received his M.S. in inorganic chemistry from the University of Missouri - St. Louis and his Ph.D. in organic chemistry from Duke University.